Home › Lilly's CYRAMZA (ramucirumab) Receives Fourth FDA Approval
 

Keywords :   


Lilly's CYRAMZA (ramucirumab) Receives Fourth FDA Approval

2015-04-27 05:33:40| drugdiscoveryonline Home Page

Eli Lilly and Company (NYSE: LLY) has received its fourth U.S. Food and Drug Administration (FDA) approval for CYRAMZA® (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.

Tags: fourth approval receives fda

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.06FLAG hosts annual Members Meeting in Buffalo
28.06Fedrigoni announces acquisition, analyzing the supply chain and more
28.06Jotun Launches CX-Rated Anticorrosive Powder Coating
28.06RPM to Announce Fiscal 2024 4Q, Year-End Results
28.06Edale appoints Maggie Reed sales manager, expands US presence
28.06Taktiful wins PRINTING United Alliance Pinnacle Product Award
28.06Evonik Commissions New Plant for AEROSIL Silicas
28.06Nice-Pak Announces Closure of German Plant
More »